GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China’s Core Innovative Drug Assets

GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China’s Core Innovative Drug Assets

HONG KONG, Feb 6, 2026 – (ACN Newswire) – According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672. HK). GIC purchased 64,128,000 shares at an average price of approximately HK$12.18 per share…
Read More

Zaļā Josta - Reklāma